Document:

Form of Officer's Certificate under Indenture

 Exhibit 4.1 
  

LABORATORY CORPORATION OF AMERICA HOLDINGS 
  
 OFFICERS’ CERTIFICATE 
  
 Pursuant to Sections 2.01, 2.02 and 12.07 of the Indenture dated as of December 5, 2005 (the “Indenture”) between Laboratory
Corporation of America Holdings (the “Company”) and The Bank of New York Trust Company, N.A., as Trustee (the “Trustee”), the undersigned officers of the Company do hereby certify as follows in connection with the
issuance of the Company’s 5.625% Senior Notes (the “Securities”) under the Indenture: 
  
 1. All conditions precedent under the Indenture to the issuance and authentication of the Securities and the delivery of the Securities to the Company
have been complied with. 
  
 2. The undersigned have read the
conditions referred to in paragraph 1 above. 
  
 3. The statements
of the undersigned contained herein are based upon their participation in the issuance of the Securities and a review of the Indenture. 
  
 4. Each of the undersigned has made such examination or investigation as is necessary in the undersigned’s opinion to enable the undersigned to
express an informed opinion as to whether the conditions referred to in paragraph 1 above have been complied with. 
  
 5. The terms of the Securities are as follows: 
  

			
	 Title:
	  	5.625% Senior Notes Due 2015
		
	 CUSIP Number:
	  	 50540RAF9

		
	 Initial Limit of Aggregate Principal Amount:
	  	 $250,000,000

		
	 Principal Payment Date:
	  	December 15, 2015, unless redeemed earlier at the option of the Company.
		
	 Interest:
	  	5.625% per annum, accruing from December 14, 2005, payable on June 15 and December 15 of each year to holders of record on the next preceding June 1 or December 1, commencing June 15,
2006.
		
	 Place of Payment of Principal, Premium and Interest:
	  	 New York, New York

		
	Optional Redemption:	  	The Company may redeem some or all of the Securities at any time prior to maturity at a redemption price equal to the greater of the principal amount of

			
	 	  	the Securities being redeemed plus accrued and unpaid interest to the redemption date or the Make-Whole Amount based on a Make-Whole Redemption Spread of 20 basis points in accordance with
Section 3.01(b) of the Indenture.
		
	Offer to Repurchase:	  	If we experience a change of control and the Notes are rated below investment grade by Standard & Poor’s Rating Service and Moody’s Investors Service, Inc., we must offer to
repurchase all of the Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest to the repurchase date. See “Description of the Notes Offer to Repurchase Upon a Change of Control Repurchase
Event.”
		
	Form:	  	The Securities will be issued as global securities that will be deposited with and registered in the name of the Depository Trust Company. Beneficial interests in the Securities will be shown
on, and transfers will be effected through, records maintained by the Depository Trust Company and its participants.

  
 6. The Securities and
the Trustee’s certificate of authentication to be borne by the Securities shall be substantially of the tenor and purport as set forth in Exhibit A of this Officers’ Certificate. 

 Dated: December 14, 2005 
  

									
	 	 	 	 	Laboratory Corporation of America Holdings
					
	 	 	 	 	 	 	By:	 	 
	 	 	 	 	 	 	 	 	Name: William B. Hayes
	 	 	 	 	 	 	 	 	 Title:   Executive Vice President and
             Chief Executive Officer

	 	 	 	 	 
					
	 	 	 	 	 	 	By:	 	 
	 	 	 	 	 	 	 	 	Name: Bradford T. Smith
	 	 	 	 	 	 	 	 	Title:   Executive Vice President and Secretary

 Exhibit A 
  

EXCEPT AS OTHERWISE PROVIDED IN SECTION 2.11 OF THE INDENTURE, THIS SECURITY MAY BE TRANSFERRED, IN WHOLE BUT NOT IN PART, ONLY TO THE DEPOSITARY, ANOTHER NOMINEE OF
THE DEPOSITARY OR TO A SUCCESSOR DEPOSITARY OR TO A NOMINEE OF SUCH SUCCESSOR DEPOSITARY 
  
 CUSIP No. 50540RAF9 
 ISIN No. US50540RAF91 
  

			
	No. G-1	 	$250,000,000

  
 5.625% Senior Note due
2015 
  
 Laboratory Corporation of America Holdings, a Delaware
corporation, promises to pay to CEDE & CO., or registered assigns, the principal amount set forth on Schedule I hereto on December 15, 2015. 
  
 Interest Payment Dates: June 15 and December 15, commencing June 15, 2006. 
  
 Record Dates: June 1 and December 1. 
  
 Additional provisions of this Security are set forth on the other side of this Security. 
  
 Dated: December 14, 2005 
  

									
	 TRUSTEE’S CERTIFICATE OF
AUTHENTICATION
	 	 	 	 LABORATORY CORPORATION
OF AMERICA HOLDINGS

				
	 The Bank of New York Trust Company,
	 	 	 	By:	 	 
	      N.A., as Trustee, certifies that this is
	 	 	 	 	 	Name:
	      one of the Securities referred to in the
	 	 	 	 	 	Title
	     Indenture.	 	 	 	 	 	 
					
	By:	 	 	 	 	 	By:	 	 
	 	 	Authorized Signatory	 	 	 	 	 	Name:
	 	 	 	 	 	 	 	 	Title

 [FORM OF REVERSE OF SECURITY] 
  
 5.625% Senior Note due 2015 
  

	1.	Indenture 

  
 This Security is one of a duly authorized series of debt securities of Laboratory Corporation of America Holdings, a Delaware corporation (such corporation, and its successors and assigns under the Indenture
hereinafter referred to, being herein called the “Company”), designated as the 5.625% Senior Notes due 2015 (the “Securities”) issued under an Indenture dated as of December 5, 2005 (“Indenture”), between the
Company and the Trustee. The terms of the Securities include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture Act of 1939 as in effect on the date of the Indenture (the “Act”). Terms
defined in the Indenture and not defined herein have the meanings ascribed thereto in the Indenture. The Securities are subject to all such terms, and Securityholders are referred to the Indenture and the Act for a statement of those terms.

  
 The Securities are general unsecured obligations of the
Company. The Company shall be entitled, without notice to or consent of the Securityholders, to issue additional debt securities under the Indenture on the same terms and conditions as the Securities (except for the interest accrual date and first
interest payment date) and with the same CUSIP number as the Securities. The Securities and any additional debt securities will be treated as a single series of debt securities for all purposes under the Indenture. The Indenture contains covenants
that limit the ability of the Company and its Restricted Subsidiaries to create liens on assets and engage in Sale and Leaseback Transactions. The Indenture also contains a covenant that limits the ability of the Company’s Subsidiaries from
incurring indebtedness or issuing preferred stock. These covenants are subject to important exceptions and qualifications. 
  

	2.	Interest 

  
 The Company promises to pay interest on the principal amount of this Security at the rate per annum shown above. The Company will pay interest semiannually on June 15 and December 15 of each year, commencing
June 15, 2006. Interest on the Securities will accrue from the most recent date to which interest has been paid or, if no interest has been paid, from December 14, 2005. Interest will be computed on the basis of a 360-day year of twelve
30-day months. The Company will pay interest on overdue principal at the rate borne by the Securities plus 1% per annum, and it will pay interest on overdue installments of interest at the same rate to the extent lawful. 
  

 R-1 

	3.	Method of Payment 

  
 The Company will pay interest on the Securities (except defaulted interest) to the Persons who are registered holders of Securities at the close of
business on the June 1 or December 1 next preceding the interest payment date even if Securities are canceled after the record date and on or before the interest payment date. Holders must surrender Securities to a Paying Agent to collect
principal payments. The Company will pay principal and interest in money of the United States that at the time of payment is legal tender for payment of public and private debts. Payments in respect of the Securities represented by a Global Security
(including principal, premium and interest) will be made by wire transfer of immediately available funds to the accounts specified by The Depository Trust Company. The Company will make all payments in respect of a certificated Security (including
principal, premium and interest) by mailing a check to the registered address of each Holder thereof; provided that payments on a certificated Security will be made by wire transfer to a U.S. dollar account maintained by the payee with a bank in the
United States if such Holder elects payment by wire transfer by giving written notice to the Trustee or the Paying Agent to such effect designating such account no later than 30 days immediately preceding the relevant due date for payment (or such
other date as the Trustee may accept in its discretion). 
  

	4.	Paying Agent and Registrar 

  
 Initially, The Bank of New York Trust Company, N.A., a national banking association (the “Trustee”), will act as Paying Agent and Registrar. The
Company may appoint and change any Paying Agent, Registrar or co-registrar without notice. The Company or any of its domestically incorporated wholly owned Subsidiaries may act as Paying Agent, Registrar or co-registrar. 
  

	5.	Optional Redemption 

  
 In accordance with Section 2.01(b) of the Indenture, the Securities are subject to redemption, in whole or in part, at the option of the Company, at
any time at a redemption price equal to the greater of (1) 100% of the principal amount of the Securities being redeemed plus accrued and unpaid interest to the redemption date or (2) the Make-Whole Amount for the Securities being
redeemed. 
  
 For purposes of calculating the “Adjusted
Treasury Rate” for the 5.625 % Senior Notes due 2015, the make-whole spread shall be 20 basis points; and Banc of America Securities LLC shall be one of the three Reference Treasury Dealers selected by the Company as long as Banc of
America Securities LLC remains a nationally recognized investment banking firm that is a primary U.S. Government securities dealer. 
  

 R-2 

	6.	Notice of Redemption 

  
 Notice of redemption will be mailed at least 30 days but not more than 60 days before the redemption date to each Holder of Securities to be redeemed at
his registered address. Securities in denominations larger than $1,000 principal amount may be redeemed in part but only in whole multiples of $1,000. If money sufficient to pay the redemption price of, which shall include accrued interest on, all
Securities (or portions thereof) to be redeemed on the redemption date is deposited with the Paying Agent on or before the redemption date and certain other conditions are satisfied, on and after such date interest ceases to accrue on such
Securities (or such portions thereof) called for redemption. 
  

	7.	Repurchase at Option of Holder Upon Change of Control Repurchase Event 

  
 (a) Upon the occurrence of a Change of Control Repurchase Event, unless the Company has exercised its right to redeem all Securities as provided in
Section 5 above, the Company will make an offer (a “Change of Control Offer”) to each Holder to repurchase all or any part (in multiples of $1,000 principal amount) of such Holder’s Securities at a repurchase price in cash equal
to 101% of the aggregate principal amount thereof plus accrued and unpaid interest, if any, on the Securities repurchased to the date of purchase (the “Change of Control Payment”). Within 30 days following any Change of Control Repurchase
Event or, at the Company’s option, prior to any Change of Control but after the public announcement thereof, the Company shall mail a notice to each Holder describing the transaction or transactions that constitute or may constitute the Change
of Control Repurchase Event and stating: 
  
 (1)
if mailed prior to the date of consummation of the Change of Control, that the offer to purchase is conditioned on the Change of Control Repurchase Event occurring on or prior to the payment date specified in the notice; 
  
 (2) that the Change of Control Offer is being made pursuant
to this Section 7 and that all Securities tendered will be accepted for payment; 
  
 (3) the purchase price and the purchase date, which shall be no earlier than 30 days and no later than 60 days from the date such notice
is mailed (the “Change of Control Payment Date”); 
  
 (4) that any Security not tendered will continue to accrue interest; 
  
 (5) that, unless the Company defaults in the payment of the Change of Control Payment, all Securities accepted for payment pursuant

  

 R-3 

 
to the Change of Control Offer will cease to accrue interest after the Change of Control Payment Date; 
  
 (6) that Holders electing to have any Securities purchased
pursuant to a Change of Control Offer will be required to surrender the Securities, with the form entitled “Option of Holder to Elect Purchase” attached to the Securities completed, to the Paying Agent at the address specified in the
notice prior to the close of business on the third Business Day preceding the Change of Control Payment Date; and 
  
 (7) that Holders will be entitled to withdraw their election if they deliver to the Paying Agent, not later than the close of business on
the second Business Day preceding the Change of Control Payment Date, a telegram, telex, facsimile transmission or letter setting forth the name of the Holder, the principal amount of Securities delivered for purchase, and a statement that such
Holder is withdrawing his election to have the Securities purchased. 
  
 The Company shall comply with the requirements of Rule 14e-1 under the Securities Exchange Act of 1934 (the “Exchange Act”) and any other federal and state securities laws and regulations thereunder to the extent those laws and
regulations are applicable in connection with the repurchase of the Securities as a result of a Change in Control Event. To the extent that the provisions of any securities laws or regulations conflict with the provisions of this Section 7, the
Company shall comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations under this Section 7 and all other provisions of the Indenture applicable to a Change of Control Offer made by the
Company by virtue of such conflict. 
  
 (b) On the Change of
Control Payment Date, the Company shall, to the extent lawful: 
  
 (1) accept for payment all Securities or portions thereof properly tendered pursuant to the Change of Control Offer; 
  
 (2) deposit with the Paying Agent an amount equal to the Change of Control Payment in respect of all Securities or portions of Securities
properly tendered; and 
  
 (3) deliver or cause
to be delivered to the Trustee the Securities properly accepted together with an Officers’ Certificate stating the aggregate principal amount of Securities or portions of Securities being purchased by the Company. 
  
 The Paying Agent shall promptly deliver to each Holder of Securities properly
tendered the Change of Control Payment for such Securities, and the 

  

 R-4 

 
Trustee will promptly authenticate and deliver to each Holder a new Security equal in principal amount to any unpurchased portion of the Securities
surrendered, if any; provided that each new Security will be in a principal amount of $1,000 or a multiple thereof. 
  
 (c) Notwithstanding anything to the contrary in this Section 7, the Company will not be required to make a Change of Control Offer upon a Change of
Control Repurchase Event if a third party makes the Change of Control Offer in the manner, at the times and otherwise in compliance with the requirements set forth in this Section 7 and all other provisions of the Indenture applicable to a
Change of Control Offer made by the Company and such third party purchases all Securities validly tendered and not withdrawn under its Change of Control Offer. 
  

(d) For purposes of the foregoing: 
  
 “Change of Control Repurchase Event” means the occurrence of a Change of Control and a Below Investment Grade Rating Event. 
  
 “Below Investment Grade Rating Event” means the Securities are
rated below Investment Grade by both Rating Agencies on any date from the date of the public notice of an arrangement that could result in a Change of Control until the end of the 60-day period following public notice of the occurrence of a Change
of Control (which period shall be extended so long as the rating of the Securities is under publicly announced consideration for possible downgrade by either of the Rating Agencies). 
  
 “Change of Control” means the occurrence of any of the following: 
  
 (1) the direct or indirect sale, transfer, conveyance or
other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of our properties or assets and those of the Subsidiaries of the Company, taken as a whole, to any
“person” (as that term is used in Section 13(d)(3) of the Exchange Act), other than the Company or a Subsidiary Guarantor that is a wholly owned Subsidiary of the Company; 
  
 (2) the adoption of a plan relating to the liquidation or dissolution of the Company; 
  
 (3) the consummation of any transaction (including, without
limitation, any merger or consolidation) the result of which is that any “person” (as that term is used in Section 13(d)(3) of the Exchange Act), other than the Company or a Subsidiary Guarantor that is a wholly owned Subsidiary of
the Company, becomes the beneficial owner, directly or indirectly, of more than 50% of the Voting Stock of the Company, measured by voting power rather than number of shares; or 
  

 R-5 

 (4) the first day on which a majority of the members of the Board of Directors are not
Continuing Directors. 
  
 Notwithstanding the foregoing, a
transaction effected to create a holding company for the Company will not be deemed to involve a Change of Control if (1) pursuant to such transaction the Company becomes a wholly owned Subsidiary of such holding company and (2) the
holders of the Voting Stock of such holding company immediately following such transaction are the same as the holders of the Voting Stock of the Company immediately prior to such transaction. 
  
 “Continuing Directors” means, as of any date of determination, any
member of the Board of Directors who: 
  
 (1) was
a member of the Board of Directors on the first date that any of the Securities issued; or 
  
 (2) was nominated for election or elected to the Board of Directors with the approval of a majority of the Continuing Directors who were
members of the Board of Directors at the time of such nomination or election. 
  
 “Investment Grade” means a rating of Baa3 or better by Moody’s (or its equivalent under any successor rating categories of Moody’s) and BBB- or better by S&P (or its equivalent under any
successor rating categories of S&P) (or, in each case, if such Rating Agency ceases to rate the Securities for reasons outside of the control of the Company, the equivalent investment grade credit rating from any Rating Agency selected by the
Company as a replacement Rating Agency). 
  
 “Moody’s” means Moody’s Investor Services Inc. 
  
 “Rating Agency” means: 
  
 (1) each of Moody’s and S&P; and 
  
 (2) if either of Moody’s or S&P ceases to rate the Securities or fails to make a rating of the Securities publicly available for reasons outside of our control, a “nationally recognized statistical
rating organization” within the meaning of Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act selected by the Company as a replacement agency for Moody’s or S&P, or both, as the case may be. 
  
 “S&P” means Standard & Poor’s Ratings Services, a
division of McGraw-Hill, Inc. 
  
 “Voting Stock” as
applied to stock of any Person, means shares, interests, participations or other equivalents in the equity interest (however designated) in such person having ordinary voting power for the election of a majority of the 

  

 R-6 

 
directors (or the equivalent) of such person, other than shares, interests, participations or other equivalents having such power only by reason of the
occurrence of a contingency. 
  

	8.	Denominations; Transfer; Exchange 

  
 The Securities are in registered form without coupons in denominations of $1,000 principal amount and whole multiples of $1,000. A Holder may transfer or
exchange Securities in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements or transfer documents and to pay any taxes and fees required by law or permitted by the Indenture. The
Registrar need not register the transfer of or exchange any Securities selected for redemption (except, in the case of a Security to be redeemed in part, the portion of the Security not to be redeemed) or any Securities for a period of 15 days
before a selection of Securities to be redeemed or 15 days before an interest payment date. 
  

	9.	Persons Deemed Owners 

  
 The registered Holder of this Security may be treated as the owner of it for all purposes. 
  

	10.	Unclaimed Money 

  
 If money for the payment of principal or interest remains unclaimed for two years, the Trustee or Paying Agent shall pay the money back to the Company at
its request unless an abandoned property law designates another Person. After any such payment, Holders entitled to the money must look only to the Company and not to the Trustee for payment. 
  

	11.	Discharge and Defeasance 

  
 Subject to certain conditions, the Company at any time shall be entitled to terminate some or all of its obligations under the Securities and the
Indenture if the Company deposits with the Trustee money or Government Obligations for the payment of principal and interest on the Securities to redemption or maturity, as the case may be. 
  

	12.	Amendment, Waiver 

  
 Subject to certain exceptions set forth in the Indenture, (i) the Indenture with respect to the Securities and the Securities may be amended with the
written consent of the Holders of at least a majority in principal amount outstanding of the Securities and (ii) any default or noncompliance with any provision of the Indenture with respect to the Securities may be waived with the written
consent of the Holders of a majority in principal amount outstanding of the Securities. 

  

 R-7 

 
Subject to certain exceptions set forth in the Indenture, without the consent of any Securityholder, the Company and the Trustee shall be entitled to amend
the Indenture or the Securities to cure any ambiguity, defect or inconsistency, or to comply with Article V of the Indenture, or to provide for uncertificated Securities in addition to or in place of certificated Securities, or to add additional
covenants or to surrender rights and powers conferred on the Company or to add additional events of defaults or to add guarantees or to add to, delete from or revise the terms of a series of debt securities to be issued under the Indenture prior to
the issuance thereof or to make any change that does not adversely affect the rights of any Securityholder in any material respect or to provide for the issuance of a new series of debt securities under the Indenture or to evidence the appointment
of a successor Trustee. 
  

	13.	Defaults and Remedies 

  
 Under the Indenture, Events of Default for the Securities include (i) default for 30 days in payment of interest on the Securities; (ii) default
in payment of principal on the Securities, upon redemption pursuant to paragraph 5 of the Securities, upon acceleration or otherwise; (iii) failure by the Company to comply with other agreements in the Indenture or the Securities, in certain
cases subject to notice and lapse of time; (iv) certain accelerations of other Indebtedness of the Company or any of its Subsidiaries if the amount accelerated (or so unpaid) is at least $50.0 million; (v) failure by the Company or any
Subsidiary to pay at maturity at least $50.0 million of other Indebtedness; and (vi) certain events of bankruptcy or insolvency with respect to the Company. 
  
 Securityholders may not enforce the Indenture or the Securities except as provided in the Indenture. The Trustee may refuse
to enforce the Indenture or the Securities unless it receives indemnity or security satisfactory to it. Subject to certain limitations, Holders of a majority in principal amount of the Securities may direct the Trustee in its exercise of any trust
or power with respect to the Securities. The Trustee may withhold from Securityholders notice of any continuing Default (except a Default in payment of principal or interest) if it determines that withholding notice is in the interest of the
Holders. 
  

	14.	Trustee Dealings with the Company 

  
 Subject to certain limitations imposed by the Act, the Trustee under the Indenture, in its individual or any other capacity, may become the owner or
pledgee of Securities and may otherwise deal with and collect obligations owed to it by the Company or its Affiliates and may otherwise deal with the Company or its Affiliates with the same rights it would have if it were not Trustee. 
  

	15.	No Recourse Against Others 

  
 An incorporator, stockholder, officer or director, as such, of the Company or the Trustee shall not have any liability for any obligations of the Company

  

 R-8 

 
under the Securities or the Indenture or for any claim based on, in respect of or by reason of such obligations or their creation. By accepting a Security,
each Securityholder waives and releases all such liability. The waiver and release are part of the consideration for the issue of the Securities. 
  

	16.	Authentication 

  
 This Security shall not be valid until an authorized signatory of the Trustee (or an Authenticating Agent) manually signs the certificate of
authentication on the other side of this Security. 
  

	17.	Abbreviations 

  
 Customary abbreviations may be used in the name of a Securityholder or an assignee, such as TEN COM (=tenants in common), TEN ENT (=tenants by the
entireties), JT TEN (=joint tenants with rights of survivorship and not as tenants in common), CUST (=custodian), and U/G/M/A (=Uniform Gifts to Minors Act). 
  

	18.	CUSIP Numbers 

  
 Pursuant to a recommendation promulgated by the Committee on Uniform Security Identification Procedures, the Company has caused CUSIP numbers to be
printed on the Securities and has directed the Trustee to use CUSIP numbers in notices of redemption as a convenience to Securityholders. No representation is made as to the accuracy of such numbers either as printed on the Securities or as
contained in any notice of redemption and reliance may be placed only on the other identification numbers placed thereon. 
  

	19.	Governing Law 

  
 THIS SECURITY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK BUT WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES
OF CONFLICTS OF LAW TO THE EXTENT THAT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY. 
  

 R-9 

 ASSIGNMENT FORM 
  

To assign this Security, fill in the form below: 
  
 I or we assign and transfer this Security to 
  
 (Print or type assignee’s name, address and zip code) 
  
 (Insert assignee’s soc. sec. or tax I.D. No.) 
  
 and irrevocably appoint
                                         agent to
transfer this Security on the books of the Company. The agent may substitute another to act for him. 
  
                                       
                                        
                                        
                                        
                                        
                                        
                    
  
 Date:                                     
                                        
                               Your
Signature:                                      
                                        
                              
  
                                       
                                        
                                        
                                        
                                        
                                        
                    
  
 Sign exactly as your name appears on the face of this Security. 
  

 R-10 

 Option of Holder to Elect Purchase 
  
 The undersigned elects to have this Security or the portion hereof (which is a multiple of $1,000 principal amount)
designated below purchased by the Company upon a Change of Control Repurchase Event pursuant to Section 7 on the reverse of this Security: 
  
 Date:
                         
  
 Your Signature:                         

 (Sign exactly as your name appears on the face of this Security) 
 Tax Identification No.:                          
 Signature Guarantee*:                          
  

	*	Participant in a recognized Signature Guarantee Medallion Program (or other signature guarantor acceptable to the Trustee). 

  
 Principal amount to be purchased (if less than all):
$        ,000 
  

 R-11 

 LABORATORY CORPORATION OF AMERICA HOLDINGS 
 5.625% SENIOR NOTE DUE 2015 
  

	 No. G-1 
	 Schedule I* 

  

					
	 Date

	 	 Principal amount of this
 Global Security

	 	 Notation

	December 14, 2005	 	$250,000,000	 	Original issuance

	*	To be attached to Global Security only. 

  

 I-1Asset Purchase Agreement

 Exhibit 10.1 
  
 ASSET PURCHASE AGREEMENT 
  
 This ASSET PURCHASE AGREEMENT dated as of December 9, 2005, is by and between MEDICINE MADE EASY, a California corporation (“Buyer”), and
PRIORITY PHARMACY, INC., a California corporation (“Seller”), The David C. Zeiger Trust UTD 4/30/93 (the “Seller’s Shareholder”), David C. Zeiger (“David”) and Peter Ellman (“Peter”). 
  
 Seller is a licensed California pharmacy located at 3935 First Avenue, San
Diego, California. 
  
 Buyer desires to purchase and Seller
desires to sell, transfer and deliver to Buyer Seller’s right title and interest in and to certain of its business and assets used in connection with or related to its HIV/AIDS business, including without limitation its inventory, customer
lists, books and records, files and goodwill used in connection with or related to its HIV/AIDS business, on the terms and conditions set forth in this Agreement. 
  
 The parties agree as follows: 
  
 ARTICLE I 
  
 DEFINITIONS 
  
 The terms defined in this Article I, whenever used herein (including the schedules hereto, unless otherwise defined therein), shall have the following meanings: 
  
 1.1 “Additional Payments” shall have the meaning set forth in Section 2.2(b) of this Agreement

  
 1.2 “Affiliate” shall mean any Person that
directly or indirectly controls, is controlled by or is under common control with another Person. 
  
 1.3 “Acquired Assets” shall mean all of Seller’s right, title and interest in and to its Inventory, supplies, packaging and shipping
materials, manufacturers warranties, customer lists, books and records, files and goodwill used in connection with or related to its HIV/AIDS business. 
  
 1.4 “Business Day” shall mean any day other than a Saturday, Sunday or other day on which banks are closed or are authorized to be closed
in New York, New York. 
  
 1.5 “Buyer Claimant”
shall have the meaning set forth in Section 8.2 of this Agreement. 
  
 1.6 “Closing” shall mean the closing of the purchase and sale of the Acquired Assets, as contemplated by this Agreement. 
  
 1.7 “Closing Date” shall have the meaning set forth in Section 3.1 of this Agreement. 

 1.8 “Code” shall mean the Internal Revenue Code of 1986, as amended. 
  
 1.9 “Contract” shall have the meaning set forth in
Section 4.3 of this Agreement. 
  
 1.10 “Employee
Benefit Plan” means any “employee benefit plan” within the meaning of Section 3(3) of ERISA, and any other bonus, profit sharing, compensation, pension, severance, deferred compensation, fringe benefit, insurance, welfare,
medical, post-retirement health or welfare benefit, medical reimbursement, health, life, stock option, stock purchase, tuition refund, service award, company car, scholarship, relocation, disability, accident, sick pay, sick leave, vacation,
termination, individual employment, executive compensation, incentive, bonus, commission, payroll practices, retention or other plan, agreement, policy, trust fund or arrangement, whether written or unwritten, and whether maintained, sponsored or
contributed to by Seller or any entity that would be deemed a “single employer” with Seller under Section 414(b), (c), (m) or (o) of the Code or Section 4001(a)(14) of ERISA (an “ERISA Affiliate”) on behalf of
any of the current, former or retired employees of Seller or its beneficiaries or with respect to which Seller or any ERISA Affiliate has or has had any obligation on behalf of any such employee or beneficiary. 
  
 1.11 “Encumbrance” shall mean any lien, charge, encumbrance,
option, right of first refusal, security interest, easement, obligation or claim or other third party right of any kind. 
  
 1.12 “Environment” shall mean any surface or subsurface physical medium or natural resource, including, air, land, soil, surface waters,
ground waters, stream and river sediments, and biota. 
  
 1.13
“Environmental Laws” shall mean any federal, state, local or foreign law, rule, regulation, ordinance, code, order or judgment (including the common law and any judicial or administrative interpretations, guidances, directives or
opinions) relating to the injury to, or the pollution or protection of human health and safety or the Environment. 
  
 1.14 “Environmental Liabilities” shall mean any claims, judgments, damages (including punitive damages), losses, penalties, fines,
liabilities, encumbrances, liens, violations, costs and expenses (including attorneys and consultants fees) of investigation, remediation or defense of any matter relating to human health, safety or the Environment of whatever kind or nature by any
party, entity or authority, (a) which are incurred as a result of (i) the existence of Hazardous Substances in, on, under, at or emanating from any real property presently or formerly owned or operated by Seller or any of its Affiliates,
(ii) the offsite transportation, treatment, storage or disposal of Hazardous Substances generated by Seller or any of its Affiliates, or (iii) the violation of any Environmental Laws or (b) which arise under the Environmental Laws.

  
 1.15 “ERISA” shall mean the Employee
Retirement Income Security Act of 1974, as amended, and the regulations thereunder. 
  
 1.16 “ERISA Affiliate” shall have the meaning set forth in the definition of “Employee Benefit Plan”. 
  

1.17 “Excluded Liabilities” shall have the meaning set forth in Section 2.1(c) of this Agreement. 
  

 2 

 1.18 “Financial Statements” shall mean (a) the unaudited financial statements of
the Seller as of December 31, 2002, 2003 and 2004, and for each of the fiscal years then ended, (b) the unaudited financial statements of the Seller as of August 31, 2005, and for the eight month period then ended. 
  
 1.19 “GAAP” shall mean generally accepted accounting
principles. 
  
 1.20 “Hazardous Discharge” shall
mean any releasing, spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, migrating, disposing or dumping (including the movement of any material through or in air, soil, surface or groundwater) of
Hazardous Substances, whether on, off, under or from any real property owned, operated, leased or used at any time by Seller or its predecessors. 
  
 1.21 “Hazardous Substances” shall mean petroleum, petroleum products, petroleum-derived substances, radioactive materials, hazardous
wastes, polychlorinated biphenyls, lead based paint, urea formaldehyde, asbestos or any materials containing asbestos, and any materials, wastes or substances regulated or defined as or included in the definition of “hazardous substances,”
“hazardous materials,” “hazardous constituents,” “toxic substances,” “pollutants,” “contaminants” or any similar denomination intended to classify substances by reason of toxicity, carcinogenicity,
ignitability, corrosivity or reactivity under any Environmental Laws. 
  
 1.22 “Indemnitee” and “Indemnitor” shall have the meanings set forth in Section 8.4(a) of this Agreement. 
  
 1.23 “Initial Payment” shall have the meaning set forth in Section 2.2(a) of this Agreement. 
  
 1.24 “Inventory” means Seller’s inventory related to
its HIV/AIDS business. 
  
 1.25 “Inventory
Payment” shall have the meaning set forth in Section 2.2(b) of this Agreement. 
  
 1.26 “IRS” shall mean the Internal Revenue Service 
  
 1.27 “Licenses and Permits” shall have the meaning set forth in Section 4.8 of this Agreement. 
  
 1.28 “Losses” shall have the meaning set forth in
Section 8.2 of this Agreement. 
  
 1.29 “Material
Adverse Effect” shall mean any material adverse effect, individually or in the aggregate, on the condition (financial or otherwise), business, assets, operations or prospects of Seller or the Acquired Assets. 
  
 1.30 “Monthly Information” shall mean the gross revenue and
prescription count information for Seller for the months of September, October and November 2005. 
  
 1.31 “Payment Program” shall have the meaning set forth in Section 4.13 of this Agreement. 
  

 3 

 1.32 “Person” shall mean any natural person, corporation, professional corporation,
limited or limited liability partnership, general partnership, joint venture, association, joint-stock company, limited liability company, company, trust, bank, trust company, land trust, business trust or other organization, whether or not a legal
entity, and any governmental unit or agency or political subdivision thereof. 
  
 1.33 “Purchase Price” shall have the meaning set forth in Section 2.2(b) of this Agreement. 
  
 1.34 “Related Party” shall have the meaning set forth in Section 4.10 of this Agreement. 
  
 1.35 “Seller Claimant” shall have the meaning set forth in
Section 8.3 of this Agreement. 
  
 1.36
“Taxes” (or “Tax” where the context requires) shall mean all federal, state, local, foreign or other taxes, duties, or similar charges (including, without limitation, income (whether net or gross), profits, premium,
estimated, excise, sales, use, environmental (including taxes under Code Section 59A), occupancy, franchise, license, value added stamp, windfall profits, social security, gross receipts, franchise, ad valorem, severance, capital levy,
production, transfer, gains, withholding, occupation, employment and payroll related and property taxes, alternative or add-on, minimum or estimated, import and export duties and other governmental charges and assessments) imposed by any taxing or
governmental authority on or payable by Seller or any other party with respect to the income, operations, products, assets or properties of Seller, whether attributable to statutory or nonstatutory rules and whether or not measured in whole or in
part by net income, and including interest, additions to tax or interest, and penalties with respect thereto, and including expenses associated with contesting any proposed adjustment related to any of the foregoing. 
  
 ARTICLE II 
  
 SALE AND PURCHASE OF THE ACQUIRED ASSETS 
  
 2.1 Purchase of the Acquired Assets. 
  
 (a) Upon the terms and subject to the conditions hereof, and upon the basis of the agreements, representations and
warranties contained in, and the schedules to, this Agreement, at the Closing, Seller shall sell, transfer, assign, convey and deliver to Buyer, and Buyer shall purchase and acquire from Seller, all of the Acquired Assets, in each case free and
clear of Encumbrances of any kind. 
  
 (b) Notwithstanding
anything contained in this Agreement, Seller shall not sell, transfer, assign, convey or deliver to Buyer, and Buyer shall not purchase or acquire from Seller, any of Seller’s cash or accounts receivable, and any other assets of Seller other
than the Acquired Assets. 
  
 (c) Buyer shall not be required to
assume, pay, fulfill, perform or otherwise discharge any liabilities or obligations of Seller, including of Seller’s business, of any kind 
  

 4 

 whatsoever (the “Excluded Liabilities”), and Seller shall pay, fulfill, perform and discharge such Excluded
Liabilities. The Excluded Liabilities include, without limitation: 
  
 (i) Legal, accounting, brokerage, finder’s fees, Taxes or other expenses incurred by Seller or any Affiliate, including, without limitation, in connection with this Agreement or the consummation of the transactions contemplated hereby;

  
 (ii) Any intercompany debt or other liability or obligation
of any nature between Seller and any past or present Related Party of Seller; 
  
 (iii) Liabilities or obligations incurred by Seller or any Affiliate of Seller after the Closing; 
  
 (iv) Any obligation or liability relating to any litigation or any claim arising out of any dispute, the elements of which occurred prior to the Closing,
whether or not listed on any schedule hereto and regardless of whether accruing prior to or subsequent to the Closing; 
  
 (v) Any liability for any Taxes accrued to or incurred by Seller or any Affiliate of Seller or relating to operations, products or assets of Seller or
any Affiliate of Seller or arising as a consequence of the transactions contemplated hereby; 
  
 (vi) Any liability or costs (including, without limitation, costs of remediation) arising out of or relating to a Hazardous Discharge or the release, discharge or disposal of any solid wastes or the handling, storage,
use, transportation or disposal of any of the foregoing, as these terms are defined by the Environmental Laws in, on, under or from facilities of Seller at any time prior to the Closing, regardless of whether such liability or costs arise before or
after Closing and whether or not in breach of any representation or warranty under this Agreement; 
  
 (vii) Any liability or obligation to employees, government agencies or other third parties in connection with any option plan, pension plan, other ERISA
plan or other Employee Benefit Plan, and any health, dental or life insurance benefits, whether or not insured and whether or not disclosed on any schedule hereto; 
  
 (viii) Any liability or obligation under any contract or commitment, including which relates to any default in respect of
such contract or other commitment or obligation of Seller; 
  
 (ix) Any liability or obligation to employees in the nature of accrued payroll, vacation, holiday or sick pay, worker’s compensation relating to the period prior to the Closing, whether or not listed on any schedule hereto and
regardless of whether accruing prior or subsequent to the Closing; 
  
 (x) Any trade debt, accounts payable, notes payable and bank debts; or 
  
 (xi) Any other liability or obligation. 
  

 5 

 2.2 Purchase Price. 
  
 (a) At the Closing, in consideration for the Acquired Assets (other than the Inventory), Buyer shall pay to Seller an
amount in cash equal to Six Million Five Hundred Thousand Dollars ($6,500,000) (the “Initial Payment”). 
  
 (b) In addition, (i) on each of January 8, 2006, February 8, 2006 and March 8, 2006, in consideration for the Acquired Assets
(other than the Inventory), Buyer shall pay to Seller an amount equal to Three Hundred Sixty-Six Thousand, Six Hundred Sixty-Seven Dollars ($366,667) (the “Additional Payments”) if, and only if, (A) Seller, David and Peter have,
during such three (3) month period, provided during normal business hours such reasonable assistance to Buyer as Buyer from time to time has requested to transition the business of Seller and the Acquired Assets to Buyer and (B) Seller has
delivered to Buyer within ten (10) days after the Closing Date a legal opinion of counsel to Seller and Seller’s Shareholder, covering the matters set forth in Exhibit A; and (ii) no later than on December 20, 2005, in
consideration for the Inventory, Buyer shall pay to Seller an amount equal to the wholesale acquisition cost (as calculated by Buyer based on its inventory to be concluded by December 16, 2005 and documentation provided by Seller to Buyer),
less two percent (2%) of such wholesale acquisition cost, of the Inventory that Buyer in its sole discretion elects by close of business on December 16, 2005, by notice to Seller, to purchase and acquire from Seller (the “Inventory
Payment” and, collectively with the Initial Payment and the Additional Payments, the “Purchase Price”). The Inventory shall be shipped F.O.B. seller’s facility in San Diego, California. 
  
 (c) Buyer shall provide written notice to Seller if it reasonably determines
that Seller is not fulfilling its obligations under Section 2.2(b)(i)(A), which notice shall specify in reasonable detail Buyer’s reasons for its belief that Sellers is not so fulfilling its obligations, in which case Seller shall have ten
(10) business days from the date such notice is effective to cure such performance. If such performance is not cured within such ten (10) business day period, Buyer shall have no obligation to make the remaining payments due under
Section 2.2(b)(i)(A). If a dispute arises between the parties relating to the cure of Seller’s performance under Section 2.2(b)(i)(A), such dispute shall be settled by a panel of three arbitrators with such arbitration to be held in
San Diego, California, in accordance with the Commercial Arbitration Rules of the American Arbitration Association, and judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. The decision of the
arbitrators shall be final and may be sued on or enforced by the party in whose favor it runs in any court of competent jurisdiction at the option of the successful party. In the event the arbitrators determine that Buyer wrongfully failed to make
payments to Seller under this Section 2.2(c), or if Buyer does not make the Inventory Payment to Seller when due, Buyer shall, in additional to making such payments to Seller, pay to Seller interest thereon at a rate of interest equal to
fifteen percent (15%) per annum beginning on the date such payments were originally due and continuing until any such payments are made in full. 
  
 2.3 Allocation of Purchase Price. The Purchase Price for the Acquired Assets shall be allocated for federal, state, local and foreign tax purposes
by each party among the Acquired Assets as mutually determined by Seller and Buyer, in compliance with applicable laws and generally accepted accounting principles. For all pertinent tax purposes, each party hereto shall report the purchase and sale
provided for, and with the characterization given these transactions in this Agreement, to taxing authorities on a basis consistent with such allocation, and each party agrees not to take a position inconsistent with such allocation. After the
Closing, Seller and Buyer each shall timely file form 8594 with the IRS detailing this allocation. In the event that Buyer determines, subject to Seller’s reasonable approval, that any adjustments to such allocation are 
  

 6 

 necessary, Seller shall make such modifications as are necessary, reporting the same on Seller’s form 8594 (if
required) or any tax report or return filed or to be filed by Seller in order to conform to Buyer’s allocation as adjusted. 
  
 ARTICLE III 
  
 CLOSING 
  
 3.1 The Closing. Subject to the terms and conditions of this Agreement, the Closing shall occur on December 9, 2005 (the “Closing Date”), at the offices of Buyer’s counsel, Nixon Peabody LLP, 990 Stewart
Avenue, Garden City, New York. 
  
 3.2
Obligations of Seller. At the Closing, Seller shall deliver to Buyer the following: 
  
 (a) Copies of the resolutions of the Board of Directors and shareholders of Seller certified by the secretary or assistant secretary of Seller, which resolutions shall approve and authorize the execution and delivery
of this Agreement and the consummation of the transactions contemplated hereby. 
  
 (b) All consents to the assignment to Buyer of each of the Acquired Assets. 
  
 (c) Such other instruments of assignment and conveyance as may be necessary or appropriate to fully and effectively transfer to Buyer the Acquired
Assets. 
  
 (d) All of the other documents and instruments
required to be delivered by Seller. 
  
 3.3 Obligations of
Buyer. At the Closing, Buyer shall deliver to Seller the following: 
  
 (a) The Initial Payment. 
  
 (b)
Copies of the resolutions of the Board of Directors of Buyer certified by the secretary or assistant secretary of Seller, which resolutions shall approve and authorize the execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby. 
  
 (c) All of the other
documents and instruments required to be delivered by Buyer. 
  

 7 

 ARTICLE IV 
  
 REPRESENTATIONS AND WARRANTIES REGARDING SELLER AND SELLER’S BUSINESS 
  
 Except as set forth on a disclosure schedule delivered by Seller to Buyer and attached hereto (the “Seller Disclosure
Schedule”), Seller and Seller’s Shareholder hereby represent and warrant to Buyer, as of the date hereof, as follows: 
  
 4.1 Organization and Qualification. Seller is a corporation duly organized, validly existing and in good standing under the laws of the State of
California, with full corporate power and authority to own, lease and operate its properties and assets and to conduct its business as it is now being conducted. Seller has no Affiliates, subsidiaries or equity interest in any other Person, except
as set forth on Schedule 4.1. Seller is duly qualified and in good standing as a foreign corporation and has all requisite corporate power and authority to do business in the jurisdictions set forth on Schedule 4.1, which jurisdictions are the only
jurisdictions wherein the character of the properties owned or leased or the nature of activities conducted by Seller make such qualification necessary. Seller’s Shareholder owns all the issued and outstanding capital stock of Seller.

  
 4.2 Authority. Seller has all requisite power and
authority to execute and deliver this Agreement and all documents, certificates, agreements, instruments and writings related hereto to which it is a party and to perform, carry out and consummate the transactions contemplated hereby and thereby.
The execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Seller. This Agreement has been duly and validly executed by Seller and constitutes the legal, valid and binding
obligations of Seller, enforceable against Seller in accordance with its terms. 
  
 4.3 No Breach. Neither the execution and delivery of this Agreement by Seller nor the consummation of the transactions contemplated hereby will: (a) violate any provision of the Articles of Incorporation
or Bylaws of Seller; (b) conflict with, result in a breach of or constitute a default (or an event which, with or without notice, lapse of time or both, would constitute a default) under and of Seller’s leases, agreements, arrangements,
contracts, commitments or understandings, written or oral, relating to Seller’s HIV/AIDS business (collectively, the “Contracts”) or any other material agreement, document, certificate or other instrument to which Seller is a party or
by which Seller or any of its properties or assets (including the Acquired Assets) is subject or bound; (c) result in the creation of, or give any party the right to create, any Encumbrance upon any of the Acquired Assets; (d) conflict
with, violate, result in a breach of or constitute a default under any judgment, decree, order or process of any court or governmental authority; (e) conflict with or violate any material statute, law or regulation applicable to Seller or any
of the Acquired Assets; or (f) require Seller to obtain any authorization, consent, approval or waiver from, or to make any filing with, any governmental or regulatory authority. 
  
 4.4 Financial Statements and Sales Information. Prior to the date hereof, Seller has delivered to Buyer the Financial
Statements and Monthly Information attached hereto as Schedule 4.4(a). The Financial Statements: (a) were prepared from the books and records of Seller, which books and records have been maintained in accordance with all legal and accounting
requirements and completely and accurately reflect all financial transactions of Seller, including, without limitation, the accounts 
  

 8 

 receivable, accounts payable and revenue of Seller for the periods covered by and as at the dates of the Financial
Statements; (b) were prepared in accordance with GAAP consistently applied; and (c) present fairly the financial condition of Seller and the results of its operations for the periods covered by, and as at the dates of, each of the
Financial Statements. The statements of profit and loss included in the Financial Statements do not contain any material items of special or non-recurring income or other income not earned in the ordinary course of business except as expressly
specified therein. All liabilities (whether accrued, unmatured, contingent or otherwise, and whether due or to become due) of Seller are set forth or adequately reserved against on the face of the most recent Financial Statements, except for
liabilities incurred since the date thereof in the ordinary course of business as theretofore conducted, which liabilities are not, individually or in the aggregate, materially adverse to the condition (financial or otherwise), business, assets,
operations or prospects of Seller. Seller is neither aware nor ought reasonably to be aware of any basis for the assertion against Seller of any materially adverse liability or loss contingency. The books and records of Seller are accurate and
complete and have been maintained in accordance with good business practices. The Monthly Information is accurate and complete in all material respects, subject to normal e-log and other final adjustments. 
  
 4.5 Absence of Certain Changes or Events. Since December 31,
2004: Seller’s business has been conducted and the Acquired Assets have been acquired and operated only in the ordinary and usual course consistent with past practice; neither Seller’s business nor the Acquired Assets have suffered any
event or condition that has had a Material Adverse Effect; and Seller has not become aware of any event or condition that has occurred or would reasonably be expected to occur that could result in a Material Adverse Effect. 
  
 4.6 Acquired Assets. Seller has good and freely transferable title to
all of the Acquired Assets, free and clear of all Encumbrances, and has the complete and unrestricted power and right to sell and transfer the Acquired Assets to Buyer in accordance with the terms hereof. Schedule 4.6 sets forth a complete and
accurate list of all Inventory will be mutually developed by Seller and Buyer by close of business on October 16, 2005, and will be attached hereto as Exhibit 4.6. All items included in the Inventory consist of a quality and quantity usable and
saleable in the ordinary course of business of Seller, and are not slow moving, damaged, below-standard quality or in excessive quantities. Seller’s inventory shall be considered “Inventory” only to the extent that Seller provides to
Buyer’s satisfaction, within ten (10) days after the Closing Date, for each item included in inventory: (a) the proprietary and established name of the item; (b) dosage; (c) container size; (d) number of containers;
(e) the item’s lot or control number(s); (f) the business name and address of all parties to each prior transaction involving the item, starting with the manufacturer (unless such item was acquired from Cardinal Health, in which case
transactions occurring prior to the acquisition from Cardinal Health may be omitted); and (g) the date of each previous transaction. 
  
 4.7 Litigation, Etc. Except as set forth on Schedule 4.7 and litigations including solely money damages including sums less than $50,000, there has
not been in the five years prior to the date hereof, nor is there currently, any claim, action, suit, inquiry, proceeding or, to the best of Seller’s knowledge, investigation of any kind or nature whatsoever, by or before any court or
governmental or other regulatory or administrative agency, commission or tribunal brought, asserted or initiated by Seller, or pending or, to the best of Seller’s knowledge, threatened against or involving Seller. To the best of Seller’s
knowledge, there is no valid basis for any such claim, action, suit, inquiry, proceeding or investigation. Seller is not subject to any judgment, order or decree. 
  

 9 

 4.8 Compliance with Law. Seller is and has been conducting its business, marketing and selling its
services and/or products, and owning and operating all of its assets, in compliance in all material respects with all applicable laws, rules, regulations, orders, codes, ordinances, authorizations, judgments and decrees, of all federal, state,
local, foreign or other governmental or regulatory authorities. Seller and each of its employees or agents providing services at the pharmacy, as applicable, (a) hold all permits, licenses, registrations, franchises, certificates, concessions
and other governmental approvals and authorizations (the “Licenses and Permits”) required for the operation of Seller’s business, including, without limitation, all Licenses and Permits required by federal, state and local law and all
applicable regulatory agencies, and (b) are in compliance in all material respects with all applicable laws, regulations and agreements, including without limitation the Health Insurance Portability and Accountability Act of 1996 as it relates
to the maintenance of customer and patient lists. All such Licenses and Permits are in full force and effect and Seller is not in default in any respect with respect to any such Licenses and Permits. No notice from any authority with respect to the
revocation, termination, suspension or limitation of any such Licenses and Permits has been issued or given, nor is Seller aware of the proposed or threatened issuance of any such notice. 
  
 4.9 Finders. Except as set forth in Section 4.9 of the Seller Disclosure Schedule, neither Seller, nor any of
its Affiliates, nor any of Seller’s directors or officers, has taken any action that, directly or indirectly, would obligate Buyer or any of its Affiliates to anyone acting as broker, finder, financial advisor or in any similar capacity in
connection with this Agreement or any of the transactions contemplated hereby. 
  
 4.10 Related Party Transactions; Intercompany Accounts. Except as set forth in Section 4.10 of the Seller Disclosure Schedule, there are no Contracts between Seller, on one hand, and any shareholder,
director, officer, employee, consultant or Affiliate of Seller (each, a “Related Party”), on the other, related to Seller’s business. Set forth in Section 4.10 of the Seller Disclosure Schedule is a true and complete list of each
transaction during the prior 18 months between Seller, on one hand, and any Related Party, on the other, related to Seller’s business. Except for compensation for services rendered, no amounts are owed by or to Seller to or by any Related
Party, related to Seller’s business. 
  
 4.11 Tax
Matters. All Taxes that are due or payable by Seller, whether or not disputed by Seller, have been paid in full. All tax returns to be filed in connection with Taxes have been accurately prepared and duly and timely filed. Attached hereto as
Exhibit 4.11 are Seller’s tax returns for 2002, 2003 and 2004. 
  
 4.12 Improper Payments. Neither Seller, nor any of Seller’s officers and employees nor, to the best of Seller’s knowledge, Seller’s agents have made any illegal or improper payments to, or provided any illegal or
improper benefit or inducement for, any governmental official, supplier, customer or other person, in an attempt to influence any such person to take or to refrain from taking any action relating to Seller’s business. 
  
 4.13 Payment Programs. Neither Seller, nor any of its officers or
employees, nor, to the best knowledge of Seller, agents has received written notice that it is subject to any 
  

 10 

 restriction or limitation on the receipt of payment under the Medicare or Medi-Cal programs, any other federally funded
health care program or any other third party payor (collectively, the “Payment Programs”). Seller has valid and current provider agreements with the Payment Programs. Seller is in compliance in all material respects with the conditions of
participation for the Payment Programs. Neither Seller, nor any of Seller’s officers or employees, nor, to the best knowledge of Seller, agents has received written notice that a Payment Program has requested or threatened any recoupment,
refund or set-off from Seller, or imposed any fine, penalty or other sanction on Seller, nor has Seller been excluded from participation in a payment program. Seller has not submitted to a Payment Program any false or fraudulent claim for payment,
nor has Seller at any time violated in any material respect any condition for participation, or any published rule, regulation, policy or standard of a Payment Program. 
  
 4.14 Fraud and Abuse. Neither Seller, nor any of Seller’s officers, employees or agents, has engaged in
any activities that are prohibited under Federal Medicare and Medicaid statutes, 42 U.S.C. §§ 1320a-7, 1320a-7a, 1320a-7b or the Federal False Claims Act, 31 U.S.C. § 3729 et seq., the regulations promulgated pursuant to such
statutes, or any related state or local statutes or regulations. 
  
 4.15 Physician Self-Referrals. Seller’s operations are in compliance in all material respects with and do not otherwise violate the Federal Medicare and Medicaid statutes regarding physician self-referrals, 42 U.S.C.
§§ 1395nn and 1396b(s), the regulations promulgated pursuant to such statutes, or any related state or local statutes or regulations. Neither Seller, nor any of Seller’s officers, employees or agents, has engaged in any activities
that may violate such statutes or regulations. 
  
 4.16
Controlled Substances. Seller has not engaged in any activities which are prohibited under the Federal Controlled Substances Act, 21 U.S.C. § 801 et seq., or the regulations promulgated pursuant to such statute or any related state or
local statutes or regulations concerning the dispensing and sale of controlled substances. 
  
 4.17 Customers and Suppliers. Schedule 4.17 hereto sets forth a list of Seller’s present customers and referral sources. There has not been any adverse change and there are no facts known to Seller which
may reasonably be expected to indicate that any adverse change may occur in the business relationship of Seller or, after the Closing, Buyer with any supplier or referral source named on Schedule 4.17. 
  
 4.18 Insurance. Schedule 4.18 will be delivered by Seller to
Buyer within thirty (30) days after closing and will contain a complete and correct list of all policies of insurance of any kind or nature covering Seller, including, without limitation, policies of life, fire, theft, casualty, product liability,
workmen’s compensation, business interruption, employee fidelity and other casualty and liability insurance, indicating the type of coverage, name of insured, the insurer, the premium, the expiration date of each policy and the amount of
coverage. All such policies (i) are with insurance companies reasonably believed by Seller to be financially sound and reputable and are in full force and effect; (ii) are sufficient for compliance with all requirements of law and of all
applicable agreements; (iii) are valid, outstanding and enforceable policies; and 
  

 11 

 (iv) provide full insurance coverage for the assets and operations of Seller for all risks normally insured against
by persons carrying on the same business as Seller. Complete and correct copies of such policies will be furnished to Buyer, together with Schedule 4.18 
  
 4.19 Disclosure. No representation, warranty or other statement by Seller herein or made in writing in connection herewith contains or will contain
an untrue statement of a material fact, or omits or will omit to state a material fact necessary to make the statements contained herein or therein not misleading. 
  
 ARTICLE V 
  
 REPRESENTATIONS AND WARRANTIES REGARDING BUYER 
  
 Buyer hereby represents and warrants to Seller as follows: 
  
 5.1 Organization and Qualification. Buyer is a corporation duly organized, validly existing and in good standing under the laws of the State of
California, with full corporate power and authority to own, lease and operate its properties and assets and to conduct its business as it is now being conducted. 
  
 5.2 Authority. Buyer has all requisite power and authority to execute and deliver this Agreement and to perform,
carry out and consummate the transactions contemplated hereby. The execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Buyer. This Agreement constitutes the legal, valid
and binding obligations of Buyer, enforceable against Buyer in accordance with its terms. 
  
 5.3 No Breach. Neither the execution and delivery of this Agreement by Buyer nor the consummation of the transactions contemplated herein will: (i) violate any provision of the Certificate of
Incorporation or Bylaws of Buyer; (ii) conflict with, result in a breach of or constitute a default (or an event which, with or without notice, lapse of time or both, would constitute a default) under, or give any third party the right to
terminate or modify, any material agreement or other instrument to which Buyer is a party or by which it or any of its assets is bound; (iii) conflict with, violate, result in a breach of or constitute a default under any judgment, decree,
order or process of any court or governmental authority; (iv) conflict with or violate any material statute, law or regulation applicable to the business of Buyer; or (v) require Buyer to obtain any authorization, consent, approval or
waiver from, or to make any filing with, any governmental or regulatory authority. 
  
 5.4 Finders. Neither Buyer, nor any of its Affiliates, nor any of their respective directors or officers, has taken any action that, directly or indirectly, would obligate Seller or any of its Affiliates to
anyone acting as a broker, finder, financial advisor or in any similar capacity in connection with this Agreement or any of the transactions contemplated hereby. 
  
 5.5 Disclosure. No representation, warranty or other statement by Buyer herein or made in writing in connection
herewith contains or will contain an untrue statement of a material fact, or omits or will omit to state a material fact necessary to make the statements contained herein or therein not misleading. 
  

 12 

 ARTICLE VI 
  
 COVENANTS 
  
 6.1 Obtaining Consents. Buyer and Seller shall use all reasonable efforts to obtain all consents, approvals and waivers from, and give all notices
to, and make all declarations, filings and registrations with, any governmental and regulatory agencies that are required to consummate or are otherwise related to the transactions contemplated hereby. Buyer and Seller shall coordinate and cooperate
with one another and supply such assistance as may be reasonably requested by each in connection with the foregoing. 
  
 6.2 Transfer and Retention of Records. Seller will retain all documents, databases and other media embodying any confidential or proprietary
information relating to Seller’s HIV/AIDS business, provided, however, that Buyer shall be entitled at any time during normal business hours, upon reasonable notice to Seller, to access such documents, databases and other media.
Seller shall take all actions reasonably requested by Buyer to make available to Buyer any and all records relating to Seller’s HIV/AIDS business, which may include making duplicate copies of any records retained by Seller in the form of papers
or computer media. 
  
 6.3 Employee Matters. Buyer
shall not assume or be responsible in any way for the obligations, liabilities or responsibilities (a) of any Employee Benefit Plan of Seller, (b) of Seller, any Affiliate of Seller or any fiduciary under, arising from, or with respect to
any Employee Benefit Plan of Seller or (c) to any of Seller’s officers, directors, employees and agents, arising from or related to the transactions contemplated by this Agreement. Buyer shall not be deemed to be a successor employer with
respect to the employment of any employee of Seller or with respect to any of Seller’s Employee Benefit Plans. Buyer may offer employment to any or all of Seller’s employees and former employees, but shall not be obligated to do so;
provided, however, that Buyer may not, during the ninety (90) days following the Closing Date, offer employment to the employees of Seller listed in Section 6.3 of the Seller Disclosure Schedule. 
  
 6.4 Further Assurances. Buyer and Seller shall, and shall cause
their respective Affiliates to, at the request and the expense of the other, execute and deliver such other instruments of conveyance and transfer and assumption and take such other action as may be reasonably requested so as to consummate the
transactions contemplated hereby or otherwise to consummate the intent of this Agreement. Without limiting the generality of the foregoing, the Seller will, and will cause its management to, execute management representation letters reasonably
requested by Buyer’s outside auditors in connection with the audit of Seller or otherwise as is required by applicable securities laws. In addition, prior to Closing, Buyer and Seller shall agree on the text of a letter to be sent to present
HIV/AIDS patients who are customers of Seller, advising such patients that their records have been transferred to Buyer. 
  
 6.5 Certain Covenants of Seller. Seller hereby covenants that (unless Buyer otherwise gives its written approval in its sole discretion) Seller
shall at its sole cost and expense take the actions set forth below: 
  
 (a) Seller shall pay or otherwise discharge (in full, without discount or compromise) when due all the Excluded Liabilities incurred in connection with its HIV/AIDS business. 
  

 13 

 (b) After the Closing, Seller shall afford Buyer, its attorneys, accountants, consultants and
representatives, free and full access to the Acquired Assets and books and records of Seller relating thereto, at all reasonable times upon reasonable notice and during normal business hours, and shall provide to Buyer and its representatives such
additional financial and operating data and other information as Buyer shall from time to time reasonably request. 
  
 (c) After the Closing, Seller shall use its best efforts to preserve for Buyer the goodwill of its customers and suppliers relating to the HIV/AIDS
business, and shall do all things reasonably requested by Buyer for such purpose. 
  
 (d) After the Closing, Seller shall promptly advise Buyer in writing of the commencement or threat against Seller of any suit, litigation or legal proceeding that relates to or might affect the Acquired Assets.

  
 ARTICLE VII 
  
 RESTRICTIVE COVENANTS 
  
 7.1 Non-Competition. Seller, David and Peter hereby agree that as a
material inducement to Buyer to enter into this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Seller, David and Peter covenant and agree that it and they, and each of
Seller’s Affiliates, and David’s and Peter’s Affiliates and immediate family members, shall not, for the period from the date hereof until five (5) years following the Closing Date (the “Restricted Period”), directly or
indirectly, on its own behalf or in the service of or on the behalf of others, as a director, trustee, owner (except as the owner of less than two percent (2%) of the outstanding stock of a publicly held corporation), employee, consultant,
advisor, independent contractor or in any other capacity, engage in the business of operating a pharmacy that in any way services or treats, or markets or sells AIDS/HIV products to, AIDS/HIV patients, within seventy five (75) miles of
Seller’s present pharmacy in San Diego, California (the “Restricted Territory”). 
  
 7.2 Non-Interference. Seller, David and Peter further agree that, during the Restricted Period and within the Restricted Territory, Seller, David
and Peter will not, directly or indirectly; (i) induce any former customer of or referrer of customers to Seller or customer of or referrer of customers to Buyer to patronize any Person who competes with Buyer; (ii) request or advise any
former customer of or referrer of customers to Seller or customer of or referrer of customers to Buyer to withdraw, curtail or cancel such Person’s business with Buyer; (iii) enter into any contract, the purpose or result of which would
benefit such Seller if any former customer of or referrer of customers to Seller or customer of or referrer of customers to Buyer were to withdraw, curtail, or cancel such customer’s or referrer’s business with Buyer; or (iv) disclose
to any other Person the names or addresses of any former customer of or referrers of customers to Seller or customer of or referrers of customers to Buyer, either individually or collectively. 
  

 14 

 7.3 Acknowledgements. If the provisions of this Article VII are violated, in whole or in part,
Buyer shall be entitled, upon application to any court of proper jurisdiction, to a temporary restraining order or preliminary injunction to restrain and enjoin Seller, David and Peter, and their respective Affiliates, from such violation without
prejudice as to any other remedies Buyer may have at law or in equity. In the event of a violation, Seller, David and Peter agree that it would be virtually impossible for Buyer to calculate its monetary damages and that Buyer would be irreparably
harmed. If Buyer seeks such temporary restraining order or preliminary injunction, Buyer shall not be required to post any bond with respect thereto, or, if a bond is required, it may be posted without surety thereon. If any restriction contained in
this Article VII is held by any court to be unenforceable, or unreasonable, as to time, geographic area or business limitation, Buyer, Seller, David and Peter agree that such provisions shall be and are hereby reformed to the maximum time,
geographic area or business limitation permitted by applicable laws. The parties further agree that the remaining restrictions contained in this Article VII shall be severable and shall remain in effect and shall be enforceable independently of each
other. Seller, David and Peter specifically acknowledge, represent and warrant that the covenants set forth in this Article VII are reasonable and necessary to protect the legitimate interests of Buyer, and that Buyer would not have entered into
this Agreement or paid the Purchase Price in the absence of such covenants. 
  
 ARTICLE VIII 
  
 INDEMNIFICATION

  
 8.1 Survival of Representations and
Warranties. All representations and warranties contained in Articles IV and V of this Agreement shall survive the Closing for the applicable statute of limitations, except that the representations and warranties contained in Sections 4.3, 4.4,
4.5, 4.6, 4.7, 4.8, 4.10, 4.12, 4.14, 4.15, 4.16., 4.17, 4.18 and 4.19 shall survive for only one (1) years after the Closing Date. 
  
 8.2 Indemnification by Seller and Seller’s Shareholder. Seller and Seller’s Shareholder shall indemnify and save Buyer and its
Affiliates, their respective directors, officers, employees, agents and representatives and all of their successors and assigns (collectively “Buyer Claimants” and individually a “Buyer Claimant”) harmless from and defend each of
them from and against any and all demands, claims, actions, liabilities, losses, costs, damages or expenses whatsoever (including any reasonable attorneys’ fees) (collectively, “Losses”) asserted against, imposed upon or incurred by
Buyer Claimants resulting from or arising out of (a) any inaccuracy or breach of any representation or warranty of Seller and Seller’s Shareholder contained herein; (b) any breach of any covenant or obligation of Seller contained
herein; (c) any liability of Seller arising out of events occurring, conditions existing, products sold or activities of Seller; (d) noncompliance with any applicable bulk sales or similar laws (including laws which may impose transferee
liability on Buyer or an Affiliate of Buyer or create Encumbrances on the Acquired Assets relating to Seller’s liability for sales, use or other taxes or withholdings arising out of the operations of Seller); and (e) any liability arising
out of or related to Seller’s business prior to Closing, or the assertion against a Buyer Claimant of a claim which, if valid, would constitute a liability arising out of or related to Seller’s business prior to Closing. Notwithstanding
the foregoing, (X) Seller and Seller’s Shareholder will have no indemnification obligation solely in respect of any matter referred to in clause (a) above until the aggregate amount of all Losses with respect to such matters exceeds
$75,000 and then for the amount of all such Losses, (Y) in no event 
  

 15 

 shall the aggregate indemnification to be provided by Seller and Seller’s Shareholder solely in respect of matters
referred to in clause (a) above for breach of the representations and warranties contained in Sections 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.10, 4.12, 4.14, 4.15, 4.16, 4.17, 4.18 and 4.19 exceed $1,000,000 in the aggregate, and (Z) in no event
shall the aggregate indemnification to be provided by Seller and Seller’s Shareholder solely in respect of matters referred to in clause (a) above for breach of all representations and warranties exceed in the aggregate the amount of the
Purchase Price. 
  
 8.3 Indemnification by Buyer.
Buyer shall indemnify and save Seller and its respective Affiliates and their respective directors, officers, employees, agents and representatives (collectively “Seller Claimants” and individually a “Seller Claimant”) harmless
from and defend each of them from and against any and all Losses asserted against, imposed upon or incurred by Seller Claimants resulting from or arising out of (a) any inaccuracy or breach of any representation or warranty of Buyer contained
herein; (b) any breach of any covenant or obligation of Buyer contained herein; and (c) except as described in Section 8.2 above, Buyer’s ownership of the Acquired Assets and operation of its business from and after the Closing
Date. 
  
 8.4 Indemnification Procedures. 

 
 (a) The rights and obligations of each party claiming a right to
indemnification hereunder (“Indemnitee”) from the other party (“Indemnitor”) shall be governed by the following rules: 
  
 (i) The Indemnitee shall give prompt written notice to the Indemnitor of any state of facts which Indemnitee determines will give rise to a claim by the
Indemnitee against the Indemnitor based on the indemnity agreements contained herein, stating the nature and basis of said claims and the amount thereof, to the extent known. No failure to give such notice shall affect the indemnification
obligations of Indemnitor hereunder, except to the extent such failure materially prejudices such Indemnitor’s ability successfully to defend the matter giving rise to the indemnification claim. 
  
 (ii) In the event any action, suit or proceeding is brought against the
Indemnitee, with respect to which the Indemnitor may have liability under the indemnity agreements contained herein, then upon the written acknowledgment by the Indemnitor within thirty days of the bringing of such action, suit or proceeding that it
is undertaking and will prosecute the defense of the claim under such indemnity agreements and confirming that the claim is one with respect to which the Indemnitor is obligated to indemnify and that it will be able to pay the full amount of
potential liability in connection with any such claim, the action, suit or proceeding (including all proceedings on appeal or for review which counsel for the Indemnitee shall deem appropriate) may be defended by the Indemnitor. However, in the
event the Indemnitor shall not offer reasonable assurances as to its financial capacity to satisfy any final judgment or settlement, the Indemnitee may assume the defense and dispose of the claim, after 30 days prior written notice to the
Indemnitor. The Indemnitee shall have the right to employ its own counsel in any such case, but the fees and expenses of such counsel shall be at the Indemnitee’s own expense unless (A) the employment of such counsel and the payment of
such fees and expenses both shall have been specifically authorized by the Indemnitor in connection with the defense of such action, suit or proceeding or (B) the Indemnitee shall have reasonably concluded and specifically notified the
Indemnitor that there may be specific defenses available to it which are different from or additional to those available to the Indemnitor. 
  

 16 

 (iii) In addition, in any event specified in clause (B) of the second sentence of subparagraph
(ii) above, the Indemnitor, to the extent made necessary by such different or additional defenses, shall not have the right to direct the defense of such action, suit or proceeding on behalf of the Indemnitee. If Indemnitor and Indemnitee
cannot agree on a mechanism to separate the defense of matters extending beyond the scope of indemnification, such matters shall be defended on the basis of joint consultation. 
  
 (iv) The Indemnitee shall be kept fully informed by the Indemnitor of such action, suit or proceeding at all stages
thereof, whether or not it is represented by counsel. The Indemnitor shall, at the Indemnitor’s expense, make available to the Indemnitee and its attorneys and accountants all books and records of the Indemnitor relating to such proceedings or
litigation, and the parties hereto agree to render to each other such assistance as they may reasonably require of each other in order to ensure the proper and adequate defense of any such action, suit or proceeding. 
  
 (v) The Indemnitor shall make no settlement of any claims which Indemnitor
has undertaken to defend, without Indemnitee’s consent, unless the Indemnitor fully indemnifies the Indemnitee for all losses, there is no finding or admission of violation of law by, or effect on any other claims that may be made against, the
Indemnitee and the relief granted in connection therewith requires no action on the part of and has no effect on the Indemnitee. 
  
 ARTICLE IX 
  
 MISCELLANEOUS 
  
 9.1 Expenses. Each party hereto shall pay its own expenses incurred in connection with this Agreement, except as otherwise specified in this Agreement and except that all sales, transfer and other similar
taxes, levies and charges that may be imposed, levied or assessed in connection with the consummation of the transactions contemplated hereby shall be borne by Seller. 
  
 9.2 Amendment. This Agreement may not be terminated, amended, altered or supplemented except by a written agreement
executed by the parties hereto. 
  
 9.3 Entire Agreement.
This Agreement, including the schedules hereto, and the instruments and other documents delivered pursuant to this Agreement, contain the entire agreement of the parties relating to the subject matter of this Agreement and supersede all other
agreements and understandings of any kind between the parties respecting such subject matter. Each and every representation, warranty and covenant shall be deemed to include the information contained in the schedules thereto. 
  
 9.4 Waivers. Waiver by either party of either breach of or failure to
comply with any provision of this Agreement by the other party shall not be construed as, or constitute, a continuing waiver of such provision, or a waiver of any other breach of, or failure to comply with, any other provision of this Agreement. No
waiver of any such breach or failure or of any term or condition of this Agreement shall be effective unless in a written notice signed by the waiving party and delivered, in the manner required for notices generally, to each affected party.

  

 17 

 9.5 Notices. All notices, consents, directions, approvals, instructions, requests and other
communications required or permitted by the terms of this Agreement to be given to any Person shall be in writing, and any such communication shall become effective five Business Days after being deposited in the United States mails, certified or
registered (return receipt requested), with appropriate postage prepaid for first class mail or, if delivered by hand or courier service or in the form of a telex, telecopy or telegram, when received (if received during normal business hours on a
Business Day, or if not, then on the next Business Day thereafter), and shall be directed to the following address or telex or telecopy number: 
  
 If to Seller: 
  
 Priority Pharmacy, Inc. 
 3935 First Avenue 
 San Diego, California 92103 
 Telecopier: 619-260-1693 
  
 With a copy to: 
  
 Morrison & Foerster LLP 
 12531 High Bluff Drive, Suite 100 
 San Diego, California 92130 
 Attention: Jeremy D. Glaser 
 Telecopier: 858-720-5125 
  
 If to
Buyer: 
  
 Medicine Made Easy 
 1660 Walt Whitman Road 
 Melville, New York 11747 
 Attention: Mr. Mike Moran 
 Telecopier: 631-249-5863 
  
 With a copy to: 
  
 Nixon Peabody LLP 
 990 Stewart Avenue 
 Garden City, New York 11530 
 Attention: Allan H. Cohen 
 Telecopier: 866-947-2070 
  
 or to such other
address as a party may have furnished to the other parties in writing in accordance herewith, except that notices of change of address shall only be effective upon receipt. Any notice which is so mailed shall be deemed delivered on the fourth
Business Day (or Days) after mailing; any notice which is transmitted by telecopier shall be deemed delivered when transmitted to the telecopier number specified above and acknowledgment of receipt of such facsimile is received. 
  

 18 

 9.6 Counterparts. This Agreement may be executed in two or more counterparts, and by the
different parties hereto in separate counterparts each of which when executed shall be deemed to be an original, but all of which together shall constitute one and the same document. 
  
 9.7 Governing Law; Submission to Jurisdiction. This Agreement shall be governed by, and construed in accordance
with, the law of the State of California, without regard to applicable principles of conflict of laws that might otherwise govern. 
  
 9.8 Binding Effect; Assignment. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective
successors and assigns. Neither party shall assign or transfer this Agreement nor any right or obligation hereunder by operation of law or otherwise without the consent of the other party, except that Buyer may assign its rights under this Agreement
to an Affiliate of Buyer. 
  
 9.9 Severability. If any
provision of this Agreement or any part of any such provision is held under any circumstances to be invalid or unenforceable in any jurisdiction, then: (a) such provision or part thereof shall, with respect to such circumstances and in such
jurisdiction, be deemed amended to conform to applicable laws so as to be valid and enforceable to the fullest possible extent; (b) the invalidity or unenforceability of such provision or part thereof under such circumstances and in such
jurisdiction shall not affect the validity or enforceability of such provision or part thereof under any other circumstances or in any other jurisdiction; and (c) such invalidity or enforceability of such provision or part thereof shall not
affect the validity or enforceability of the remainder of such provision or the validity or enforceability of any other provision of this Agreement. Each provision of this Agreement is separable from every other provision of this Agreement, and each
part of each provision of this Agreement is separable from every other part of such provision. 
  
 9.10 Headings. The headings contained in this Agreement (including the schedules) are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

  
 9.11 No Agency. Neither party hereto shall be
deemed hereunder to be an agent of, or partner or joint venture with, the other party hereto. 
  
 9.12 Third Parties. Nothing herein is intended or shall be construed to confer upon or give to any person other than the parties hereto any rights or remedies under or by reason of this Agreement.

  
 9.13 Passage of Title and Risk of Loss. Legal
title, equitable title and risk of loss with respect to the Acquired Assets will not pass to Buyer until the Acquired Assets are transferred at the Closing. 
  

 19 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement effective as of the date first above
written. 
  

			
	SELLER:
	
	PRIORITY PHARMACY, INC.
		
	By:	 	  

	 	 	Authorized Officer
	
	SELLER’S SHAREHOLDER:
	
	THE DAVID C. ZEIGER TRUST UTD 4/30/93
		
	By:	 	  

	 	 	David C. Zeiger
	 	 	Trustee
	
	  

 DAVID C.
ZEIGER

	
	  

 PETER
ELLMAN

	
	BUYER:
	
	MEDICINE MADE EASY
		
	By:	 	  

	 	 	Michael Moran
	 	 	President and Chief Executive Officer

  

 20 

 EXHIBIT A 
  
 1. Seller has been duly organized and is validly existing and in good standing under the laws of the State of California.
Seller has the power and authority to own, lease and operate its properties and to conduct its business as it is presently conducted. Seller’s Shareholder is the only shareholders of Seller. 
  
 2. Seller and Seller’s Shareholder have the power and authority to
execute, deliver and perform, and has taken all action necessary to execute, deliver and perform the Agreement. Seller and Seller’s Shareholder have duly executed and delivered the Agreement. 
  
 3. The Agreement constitutes the valid and binding obligation of Seller and
Seller’s Shareholder, enforceable against such Person in accordance with its terms. 
  
 4. The execution and delivery of the Agreement, and the consummation by Seller and Seller’s Shareholder’s of the transactions contemplated by the Agreement, do not, with or without the giving of notice or
the lapse of time or both, (a) violate (i) the articles of incorporation or bylaws of Seller, (ii) any Federal or state law or regulation applicable to Seller or Seller’s Shareholder, or (iii) any existing obligation of the
Seller or Seller’s Shareholder under any order, writ, judgment or decree of any court or Federal or state governmental authority, or (b) violate or result in a breach of, constitute a default under, require any consent under, or result in
the creation of a lien, charge or encumbrance on any property or assets of the Seller pursuant to, the terms of any material agreement or instrument to which the Seller or Seller’s Shareholder is a party or is bound. 
  
 5. No registration, approval, authorization, consent, notice or other action
by, or filing with, any Federal or state governmental authority is required on the part of Seller or Seller’s Shareholder in connection with the execution and delivery of the Agreement, or the consummation by Seller or Seller’s Shareholder
of the transactions contemplated by the Agreement, or if required, such appropriate action has been taken. 
  

 21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}]]